David C. Montefiori

David C. Montefiori

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

David C. Montefiori

Departments of Surgery and Integrative Immunobiology, Center for Human Systems Immunology, Duke University, Durham, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Cell
Verified
Journal Article
Open access
BKBette Tina Marie Korber
Bette Tina Marie Korber
WFWill Fischer
Will Fischer
SGSandrasegaram Gnanakaran
Sandrasegaram Gnanakaran
HYHyejin Yoon
Hyejin Yoon
JTJames Theiler
James Theiler
MWMatthew D. Wyles
Matthew D. Wyles
A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become the most prevalent form in the global pandemic. Dynamic tracking of variant frequencies revealed a recurrent pattern of G614 increase at multiple geographic levels: national, regional, and municipal. The shift occurred even in local epidemics where the original D614 form was well established prior to introduction of the G614 variant. The consistency of this pattern was highly statistically significant, suggesting that the G614 variant may have a fitness advantage. We found that the G614 variant grows to a higher titer as pseudotyped virions. In infected individuals, G614 is associated with lower RT-PCR cycle thresholds, suggestive of higher upper respiratory tract viral loads, but not with increased disease severity. These findings illuminate changes important for a mechanistic understanding of the virus and support continuing surveillance of Spike mutations to aid with development of immunological interventions.

7 January 2022 in Science
Verified
Journal Article
Open access
PGPeter B. Gilbert
Peter B. Gilbert
DMDavid C. Montefiori
David C. Montefiori
AMAdrian B. McDermott
Adrian B. McDermott
YFYouyi Fong
Youyi Fong
DBDavid Benkeser
David Benkeser
UTUnited States Government (USG)/CoVPN Biostatistics Team
United States Government (USG)/CoVPN Biostatistics Team
Antibody levels predict vaccine efficacy: Symptomatic COVID-19 infection can be prevented by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. A “correlate of protection” is a molecular biomarker to measure how much immunity is needed to fight infection and is key for successful global immunization programs. Gilbert et al . determined that antibodies are the correlate of protection in vaccinated individuals enrolled in the Moderna COVE phase 3 clinical trial (see the Perspective by Openshaw). By measuring binding and neutralizing antibodies against the viral spike protein, the authors found that the levels of both antibodies correlated with the degree of vaccine efficacy. The higher the antibody level, the greater the protection afforded by the messenger RNA (mRNA) vaccine. Antibody levels that predict mRNA vaccine efficacy can therefore be used to guide vaccine regimen modifications and support regulatory approvals for a broader spectrum of the population. —PNK

14 January 2014 in AIDS
Verified
Journal Article
Closed access
PHPeter Hraber
Peter Hraber
MSMichael S. Seaman
Michael S. Seaman
RBRobert T. Bailer
Robert T. Bailer
JMJohn R. Mascola
John R. Mascola
DMDavid C. Montefiori
David C. Montefiori
BKBette Tina Marie Korber
Bette Tina Marie Korber
Objective: Studies of neutralizing antibodies in HIV-1 infected individuals provide insights into the quality of the response that should be possible to elicit with vaccines and ways to design effective immunogens. Some individuals make high titres of exceptional broadly reactive neutralizing antibodies that are of particular interest; however, more modest responses may be a reasonable goal for vaccines. We performed a large cross-sectional study to determine the spectrum of neutralization potency and breadth that is seen during chronic HIV-1 infection. Design: Neutralization potency and breadth were assessed with genetically and geographically diverse panels of 205 chronic HIV-1 sera and 219 Env-pseudotyped viruses representing all major genetic subtypes of HIV-1. Methods: Neutralization was measured by using Tat-regulated luciferase reporter gene expression in TZM-bl cells. Serum-neutralizing activity was compared with a diverse set of human mAbs that are widely considered to be broadly neutralizing. Results: We observed a uniform continuum of responses, with most sera displaying some level of cross-neutralization, and approximately 50% of sera neutralizing more than 50% of viruses. Titres of neutralization (potency) were highly correlated with breadth. Many sera had breadth comparable to several of the less potent broadly neutralizing human mAbs. Conclusion: These results help clarify the spectrum of serum-neutralizing activity induced by HIV-1 infection and that should be possible to elicit with vaccines. Importantly, most people appear capable of making low to moderate titres of broadly neutralizing antibodies. Additional studies of these relatively common responses might provide insights for practical and feasible vaccine designs.

1 March 2014 in Journal of Virology
Verified
Journal Article
Open access
PDF file
ADAllan Decamp
Allan Decamp
PHPeter Hraber
Peter Hraber
RBRobert T. Bailer
Robert T. Bailer
MSMichael S. Seaman
Michael S. Seaman
COChristina Ochsenbauer
Christina Ochsenbauer
DMDavid C. Montefiori
David C. Montefiori
Standardized assessments of HIV-1 vaccine-elicited neutralizing antibody responses are complicated by the genetic and antigenic variability of the viral envelope glycoproteins (Envs). To address these issues, suitable reference strains are needed that are representative of the global epidemic. Several panels have been recommended previously, but no clear answers have been available on how many and which strains are best suited for this purpose. We used a statistical model selection method to identify a global panel of reference Env clones from among 219 Env-pseudotyped viruses assayed in TZM-bl cells with sera from 205 HIV-1-infected individuals. The Envs and sera were sampled globally from diverse geographic locations and represented all major genetic subtypes and circulating recombinant forms of the virus. Assays with a panel size of only nine viruses adequately represented the spectrum of HIV-1 serum neutralizing activity seen with the larger panel of 219 viruses. An optimal panel of nine viruses was selected and augmented with three additional viruses for greater genetic and antigenic coverage. The spectrum of HIV-1 serum neutralizing activity seen with the final 12-virus panel closely approximated the activity seen with subtype-matched viruses. Moreover, the final panel was highly sensitive for detection of many of the known broadly neutralizing antibodies. For broader assay applications, all 12 Env clones were converted to infectious molecular clones using a proviral backbone carrying aRenillaluciferase reporter gene (Env.IMC.LucR viruses). This global panel should facilitate highly standardized assessments of vaccine-elicited neutralizing antibodies across multiple HIV-1 vaccine platforms in different parts of the world.IMPORTANCEAn effective HIV-1 vaccine will need to overcome the extraordinary genetic variability of the virus, where most variation occurs in the viral envelope glycoproteins that are the sole targets for neutralizing antibodies. Efforts to elicit broadly cross-reactive neutralizing antibodies that will protect against infection by most circulating strains of the virus are guided in part byin vitroassays that determine the ability of vaccine-elicited antibodies to neutralize genetically diverse HIV-1 variants. Until now, little information was available on how many and which strains of the virus are best suited for this purpose. We applied robust statistical methods to evaluate a large neutralization data set and identified a small panel of viruses that are a good representation of the global epidemic. The neutralization properties of this new panel of reference strains should facilitate the development of an effective HIV-1 vaccine.

1 April 2021 in Cell Host & Microbe
Verified
Journal Article
Closed access
XSXiaoying Shen
Xiaoying Shen
HTHaili Tang
Haili Tang
CMCharlene McDanal
Charlene McDanal
KWKshitij Wagh
Kshitij Wagh
WFWilliam Fischer
William Fischer
DMDavid C. Montefiori
David C. Montefiori

2 December 2022 in Science
Verified
Journal Article
Closed access
DLDavid J. Leggat
David J. Leggat
CWCohen Kristen W
Cohen Kristen W
JWJordan R. Willis
Jordan R. Willis
WFWilliam J. Fulp
William J. Fulp
ADAllan DeCamp
Allan DeCamp
WSWilliam R Schief
William R Schief
Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B cells. In a randomized, double-blind, placebo-controlled phase 1 clinical trial, the HIV vaccine–priming candidate eOD-GT8 60mer adjuvanted with AS01 B had a favorable safety profile and induced VRC01-class bnAb precursors in 97% of vaccine recipients with median frequencies reaching 0.1% among immunoglobulin G B cells in blood. bnAb precursors shared properties with bnAbs and gained somatic hypermutation and affinity with the boost. The results establish clinical proof of concept for germline-targeting vaccine priming, support development of boosting regimens to induce bnAbs, and encourage application of the germline-targeting strategy to other targets in HIV and other pathogens.